Journal of Inherited Metabolic Disease

, Volume 30, Issue 4, pp 447–465 | Cite as

Newborn screening in North America

  • Bradford L. Therrell
  • John Adams
Newborn Screening


Newborn screening in North America dates to the early work of Bob Guthrie in the USA. Screening programmes in both the USA and Canada began in the early 1960s, with documented programmes in both countries as early as 1962. Throughout the 1960s and 1970s, many of the screening tests that later became part of routine screening around the world were developed in US and Canadian laboratories, including tests for phenylketonuria, other inborn errors of metabolism, congenital hypothyroidism, congenital adrenal hyperplasia, and haemoglobinopathies. An automated punching machine developed in the USA facilitated screening expansion by significantly reducing sample preparation time and effort. US and Canadian programmes were leaders in applying computerized data management to newborn screening in the 1980s. In the 1990s, DNA and tandem mass spectrometry testing protocols were developed in the USA and applied to newborn screening. US programmes have continually expanded over time, while most Canadian programmes have not. With impetus from private laboratories and professional and consumer groups, many US programmes now screen for more than 50 conditions and there is increased expansion activity in Canada. NBS research in the USA is focused on improving system efficiency and translating other genetic testing to NBS, particularly where new technologies and treatment therapies exist. Although national newborn screening policies do not exist in either Canada or the USA, there are intense efforts to provide uniform access to screening nationwide in both countries. New partnerships between health professionals, consumers and politicians are benefiting the overall screening systems in both countries.


Congenital Adrenal Hyperplasia Newborn Screening Inborn Error Congenital Hypothyroidism Maple Syrup Urine Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Alberta Health and Wellness (2006) Newborn metabolic screening in Alberta 2002–2005. Edmonton: Provincial Health Office, Public Health Divison.Google Scholar
  2. American Academy of Pediatrics, Newborn Screening Task Force (2000) Serving the family from birth to the medical home – Newborn screening: a blueprint for the future. Pediatrics 106(suppl): 383–427.Google Scholar
  3. American Academy of Pediatrics, Committee on Bioethics (2001) Ethical issues with genetic testing in pediatrics. Pediatrics 107: 1451–1455.CrossRefGoogle Scholar
  4. American College of Medical Genetics, Newborn Screening Working Group (2006) Newborn screening: toward a uniform screening panel and system. Genetics in Medicine 8(suppl): 1S–252S.CrossRefGoogle Scholar
  5. Andersson HC, Narumanchi TC, Cunningham A, Bowdish B, Thoene J (2006) Genetic/metabolic health care delivery during and after hurricanes Katrina and Rita. Molec Genet Metabol 88: 3–6.CrossRefGoogle Scholar
  6. Andrews LB (1985) Legal liability and quality assurance in newborn screening. Chicago: American Bar Foundation.Google Scholar
  7. Auray-Blais C, Giguere R, Lemieux B (2003) Newborn urine screening programme in the province of Quebec: an update of 30 years’ experience. J Inherit Metab Dis 26: 393–402.PubMedCrossRefGoogle Scholar
  8. Botkin JR, Clayton EW, Fost NC, et al (2006) Newborn screening technology: proceed with caution. Pediatrics 117: 1793–1799.PubMedCrossRefGoogle Scholar
  9. Brown DK, Dort JC, Sauve R (2001) Newborn hearing screening programs – a truly Canadian perspective. J Speech-Lang Pathol Audiol 24: 48–58.Google Scholar
  10. Burrow GN, Dussault JH (1980) Neonatal Thyroid Screening. New York: Raven Press.Google Scholar
  11. Carmichael SK, Johnson SB, Baughcum A, et al (2003) Prospective assessment in newborns of diabetes autoimmunity (PANDA): maternal understanding of infant diabetes risk. Genetics in Medicine 5: 77–83.PubMedCrossRefGoogle Scholar
  12. Chace DH, Millington DS (1994) Neonatal screening for inborn errors of metabolism by automated dynamic liquid secondary ion tandem mass spectrometry. In Farriaux J-P, Dhondt J-L eds. New Horizons in Neonatal Screening. Amsterdam: Elsevier Science Publishers 373–376.Google Scholar
  13. Chace DH, Millington DS, Terada N, Kahler SG, Roe CR, Hofman LF (1993) Rapid diagnosis of phenylketonuria by quantitative analysis for phenylketonuria and tyrosine in neonatal blood spots by tandem mass spectrometry. Clin Chem 39: 66–71.PubMedGoogle Scholar
  14. Chan K, Puck JM (2005) Development of population-based newborn screening for severe combined immunodeficiency. J Allerg Clin Immunol 115: 391–398.CrossRefGoogle Scholar
  15. Clow C, Scriver CR, Davies E (1969) Results of mass screening for hyperaminoacidemias in the newborn infant. Amer J Dis Child 117: 48–53.PubMedGoogle Scholar
  16. Comeau AM, Hsu HW, Schwerzler M, Mushinsky G, Grady GF (1992) Detection of HIV in specimens from newborn screening programs. N Engl J Med 326: 1703.PubMedGoogle Scholar
  17. Department of Health and Human Services (1980) State Laws and Regulations on Genetic Disorders. Washington, D.C.: U.S. Department of Health and Human Services, DHHS Publication No. (HSA) 81–5243.Google Scholar
  18. Descartes M, Huang Y, Zhang YH, et al (1992) Genotypic confirmation from original dried blood specimens in a neonatal hemoglobinopathy screening program. Pediatr Res 31: 217–221.PubMedCrossRefGoogle Scholar
  19. Dussault JH, Laberge C (1973) Thyroxine (T4) determination in dried blood by radioimmunoassay: a screening method for neonatal hypothyroidism. Union Med Can 102: 2062–2064.PubMedGoogle Scholar
  20. Dussasult JH, Coulomb P, Laberge C, Letarte J, Guyda H, Khoury K (1975) Preliminatry report on a mass screening program for neonatal hypothyroidism. J Pediatr 86: 670–674.CrossRefGoogle Scholar
  21. Dussault JH, Parlow A, Letarte J, Guyda H, Laberge C (1976) TSH measurements from blood spots on filter paper. A confirmatory screening test for neonatal hypothyroidism. J Pediatr 89: 550–552.PubMedCrossRefGoogle Scholar
  22. Efron ML, Young D, Moser HW, MacCready RA (1964) A simple chromatographic screening test for the detection of disorders of amino acid metabolism: a technique using whole blood or urine collected on filter paper. New Engl J Med 270: 1378–1383.PubMedCrossRefGoogle Scholar
  23. Fisher DA, Dussault JH, Foley TP et al (1979) Screening for congenital hypothyroidism: results of screening one million North American infants. J Pediatr 95: 404–406.CrossRefGoogle Scholar
  24. Fox JG, Hall DL, Haworth JC, Maniar A, Sekla L (1971) Newborn screening for hereditary metabolic disorders in Manitoba. 1965–1970. Can Med Assoc J 104: 1085–1088.PubMedGoogle Scholar
  25. Gaston MH, Verter JI, Wood G, et al (1986) Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. N Engl J Med 314: 1593–99.PubMedGoogle Scholar
  26. Garrick MD, Dembure P, Guthrie R (1973) Sickle cell anemia and other hemoglobinopathies: procedures and strategy for screening spots of blood on filter paper as specimens. N Engl J Med 288: 1265–1268.PubMedGoogle Scholar
  27. Green NS, Pass KA (2005). Neonatal screening by DNA microarray: spots and chips. Nature Rev Genetics 6: 147–151.CrossRefGoogle Scholar
  28. Gregg RG, Wilfond BS, Farrell PM, Laxova A, Hassemer D, Mischler EH (1993) Application of DNA analysis in a population-screening program for neonatal diagnosis of cystic fibrosis (CF): comparison of screening protocols. Am J Hum Genet 52: 616–26.PubMedGoogle Scholar
  29. Guthrie R (1962) Screening for ‘inborn errors of metabolism’ in the newborn infant - a multiple test program. Birth defects Original Article Series IV: 92–98.Google Scholar
  30. Guthrie R (1964) Routine screening for inborn errors in the newborn: ‘inhibition assays,’ ‘instant bacteria’ and multiple tests. In Oster J, ed. Proceedings of the International Copenhagen Congress on the Scientific Study of Mental Retardation. Copenhagen: Statens Andssvage Forsong, 495–499.Google Scholar
  31. Guthrie R (1992) The origin of newborn screening. Screening 1: 5–15.PubMedCrossRefGoogle Scholar
  32. Guthrie R, Susi A (1963) A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics 32: 338–343.PubMedGoogle Scholar
  33. Hanley WB (2005) Newborn screening in Canada – are we out of step? Paediatr Child Health 10: 203–207.PubMedGoogle Scholar
  34. Hanley WB, Partington MW, Rathbun JC, Amies CR, Webb JF, Moore JE (1969) The newborn phenylketonuria screening program in Ontario. Can Med Assoc J 101: 185–190.Google Scholar
  35. Haworth JC, Miller JR, Scriver CR (1974) Screening, counseling and treatment of hereditary metabolic disease; a survery of resources in Canada. Can Med Assoc J 111: 1147–1153.PubMedGoogle Scholar
  36. Holtzman C, Slazyk WE, Cordero JF, Hannon WH (1986) Descriptive epidemiology of missed cases of phenylketonuria and congenital hypothyroidism. Pediatrics 78: 553–558.PubMedGoogle Scholar
  37. Houston IB, Veale AMO (1971) Screening for inborn errors of metabolism. Lab Manag 9: 30–32 and 53.Google Scholar
  38. Hsu HW, Grady GF, Maguire JH, Weiblen BJ, Hoff R (1992) Newborn screening for congenital Toxoplasma infection: five years experience in Massachusetts, USA. Scand J Infect Dis 84 (suppl): 59–64.Google Scholar
  39. Jinks DC, Minter M, Tarver DA, Vanderford M, Hejtmancik JF, McCabe ERB (1989) Molecular genetic diagnosis of sickle cell disease using dried blood specimens from newborn screening blotters. Hum Genet 81: 363–6.PubMedCrossRefGoogle Scholar
  40. Johnson K, Lloyd-Puryear MA, Mann MY, Ramos LR, Therrell BL (2006) Financing state newborn screening programs: sources and uses of funds. Pediatrics 117 (suppl): S270–9.PubMedGoogle Scholar
  41. Joint Commission on Infant Hearing (2000) Year 2000 position statement: principles and guidelines for early hearing detection and intervention programs. Pediatrics 106: 798–817.CrossRefGoogle Scholar
  42. Koch JH (1997) Robert Guthrie: The PKU Story. Pasadena: Holt Publishing House.Google Scholar
  43. Kling S, Nash C, Jones D (1988) Newborn screening in the 80’s – the automation of follow-up. J Med Sys 12: 89–96.CrossRefGoogle Scholar
  44. Laberge C (1980) Organization and cost benefits of mass screening programs. In: Burrow GN, Dussault JH eds Neonatal Thyroid Screening. New York: Raven Press, 189–198.Google Scholar
  45. LaFranchi SH, Hanna CE, Krainz PL, Skeels MR, Miyahira RS, Sesser DE (1985) Screening for congenital hypothyroidism with specimen collection at two time periods: results of the Northwest Regional Screening Program. Pediatrics 76: 734–740.PubMedGoogle Scholar
  46. Lacey JM, Minutti CZ, Magera MJ et al (2004) Improved specificity of newborn screening for congenital adrenal hyperplasia by second-tier steroid profiling using tandem mass spectrometry. Clin Chem 50: 621–625.PubMedCrossRefGoogle Scholar
  47. Lemieux B, Auray-Blais C, Giguere R, Bernier J-P (1987) Controversies over neontatl screening for muscular dystrophy. In Therrell BL ed Advances in Neonatal Screening. Amsterdam: Elsevier Science Publishers, 355–360.Google Scholar
  48. Lemieux B, Auray-Blais C, Giguere R, Shapcott D, Scriver CR (1988) Newborn urine screening experience with over one million infants in the Quebec Network of Genetic Medicine. J Inherit Metab Dis 11: 45–55.PubMedCrossRefGoogle Scholar
  49. Lemieux B, Auray-Blais C, Giguere R, Scriver CR (1989) Neuroblastoma screening: the Canadian experience. Medical & Pediatric Oncology 17: 379–81.CrossRefGoogle Scholar
  50. Levine GD, Therrell BL (1986) Second testing for hypothyroidism. Pediatrics 78: 375–376.PubMedGoogle Scholar
  51. Li Y, Brockmann K, Turecek F, Scott CR, Gelb, MH (2004) Tandem mass spectrometry for the direct assay of enzymes in dried blood spots: application to newborn screening for Krabbe disease. Clin Chem 50: 638–640.PubMedCrossRefGoogle Scholar
  52. Magera MJ, Gunawardena ND, Hahn SH et al (2006) Quantitative determination of succinylacetone in dried blood spots for newborn screening of tyrosinemia type I. Molec Genet Metabol 88: 16–21.CrossRefGoogle Scholar
  53. Meaney FJ (1988) Computerized tracking for newborn screening and follow-up: a review. J Med Sys 12: 69–75.CrossRefGoogle Scholar
  54. McCabe ERB, Huang S-Z, Seltzer WK, Law ML (1987) DNA microextraction from dried blood spots on filter paper blotters: potential applications to newborn screening. Hum Genet 75: 213–216.PubMedCrossRefGoogle Scholar
  55. McGhee SA, Stiehm ER, Cowan M, Krogstad P, McCabe ER (2005a) Two-tiered universal newborn screening strategy for severe combined immunodeficiency. Molec Genet Metabol 86: 427–430.CrossRefGoogle Scholar
  56. McGhee SA, Stiehm ER, McCabe ER (2005b) Potential costs and benefits of newborn screening for severe combined immunodeficiency. J Pediatr 147: 603–608.PubMedCrossRefGoogle Scholar
  57. Millington DS, Kodo N, Norwood DL, Roe CR (1990) Tandem mass spectrometry: a new method for acylcarnitine profiling with potential for neonatal screening for inborn errors of metabolism. J Inherit Metabol Dis 13: 321–324.CrossRefGoogle Scholar
  58. Minutti CZ, Lacey JM, Magera MJ et al (2004) Steroid profiling by tandem mass spectrometry improves the positive predictive value of newborn screening for congenital adrenal hyperplasia. J Clin Endocriol Metabol 89: 3687–3693.CrossRefGoogle Scholar
  59. Mordaunt VL, Cunningham GC, Kan K (1988) Computer assisted management of a regionalized newborn screening program. J Med Sys 12: 77–88.CrossRefGoogle Scholar
  60. Murphey WH, Patchen L, Guthrie R (1972) Screening tests for argininosuccinic aciduria, orotic aciduria, and other inherited enzyme deficiencies using dried blood specimens. Biochem Genet 6: 51–59.PubMedCrossRefGoogle Scholar
  61. National Institutes of Health, Consensus Development Conference Statement (1987) Newborn screening for sickle cell disease and other hemoglobinopathies. J Amer Med Assoc 258: 1205–9.CrossRefGoogle Scholar
  62. National Institutes of Health, Consensus Development Conference Statement (1993) Early identification of hearing impairment in infants and young children. Internat J Pediatr Otorhinolaryngol 27: 215–227.CrossRefGoogle Scholar
  63. National Research Council, Committee for the Study of Inborn Errors of Metabolism (1975) Genetic screening: programs, principles, and research. Washington, D.C.: National Academy of Science.CrossRefGoogle Scholar
  64. Naylor EW, Guthrie R (1978) Newborn screening for maple syrup urine disease (branched-chain ketoaciduria). Pediatrics 61: 262–266.PubMedGoogle Scholar
  65. Naylor EW, Orfanos AP, Guthrie R (1977) A simple screening test for arginase deficiency (hyperargininemia). J Lab Clin Med 89: 876–880.PubMedGoogle Scholar
  66. Naylor EW, Orfanos AP, Guthrie R (1978). An improved screening test for adenosine deaminase deficiency. J Pediatr 93: 473–476.PubMedGoogle Scholar
  67. Ontario Ministry of Health, Advisory Committee on Inborn Errors of Metabolism (1973) PKU screening – is it worth it? Can Med Assoc J 108: 328–329.Google Scholar
  68. Orfanos AP, Naylor EW, Guthrie R (1978) Micromethod for estimating adenosine deaminase activity in dried blood spots on filter paper. Clin Chem 24: 591–594.PubMedGoogle Scholar
  69. Pang S, Hotchkiss J, Drash AL, Levine LS, New MI (1977) Micro filter paper method for 17-hydroxyprogesterone radioimmunoassay: its application for rapid screening for congenital adrenal hyperplasia. J Clin Endocrinol Metab 45: 1003–1008.PubMedCrossRefGoogle Scholar
  70. Rashed MS, Ozand PT, Bucknall MP, Little D (1995) Diagnosis of inborn errors of metabolism from blood spots by acylcarnitines and amino acids profiling using automated electrospray tandem mass spectrometry. Pediatr Res 38:324–31.PubMedGoogle Scholar
  71. Rinaldo P, Zafari S, Tortorelli S, Matern D (2006) Making the case for objective performance metrics in newborn screening by tandem mass spectrometry. Mental Retardation & Developmental Disabilities Research Reviews. 12: 255–261.CrossRefGoogle Scholar
  72. Scriver CR, Laberge C, Clow CL, Fraser CF (1978) Genetics and medicine: an evolving relationship. Science 200: 946–952.PubMedCrossRefGoogle Scholar
  73. Spada M, Pagliardini S, Yasuda M, et al (2006) High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet 79: 31–40.PubMedCrossRefGoogle Scholar
  74. Therrell BL (1982) Computerization in the newborn screening laboratory: an aid to data management. In Naruse H, Irie M, eds. Neonatal Screening. Amsterdam: Elsevier Science Publishers, 455–460.Google Scholar
  75. Therrell BL (1988) Hemoglobinopathy testing in newborn screening programs in the United States. In Schmidt BJ, Diament AJ, Loghin-Grosso NS, eds. Current Trends in Infant Screening. Amsterdam: Elsevier Science Publishers, 331–337.Google Scholar
  76. Therrell BL (2001) U.S. newborn screening policy dilemmas for the twenty-first century. Molec Genet Metabol 74: 64–74.CrossRefGoogle Scholar
  77. Therrell BL (2003) Data integration and warehousing: coordination between newborn screening and related public health programs. Southeast Asian J Trop Med Pub Health 34 (suppl 3): 63–68.Google Scholar
  78. Therrell BL, Brown LO (1988) Computerized newborn screening in Texas – a multiple microcomputer approach. J Med Sys 12: 115–20.CrossRefGoogle Scholar
  79. Therrell BL, Hannon WH (2006) National evaluation of US newborn screening system components. Mental Retardation and Developmental Disabilities Research Reviews 12: 236–245.PubMedCrossRefGoogle Scholar
  80. Therrell BL, Tuerck JM, McCabe ERB (1992a) Newborn screening systems in the United States. In Wilcken B, Webster D, eds. Neonatal Screening in the Nineties. Manly Vale, NSW, Australia: The Kelvin Press, 18–24.Google Scholar
  81. Therrell BL, Panny SR, Davidson A, et al (1992b) U.S. Newborn screening system guidelines: statement of the Council of Regional Networks for Genetic Services. Screening 1:135–147.CrossRefGoogle Scholar
  82. Therrell BL, Williams D, Johnson K, Lloyd-Puryear MA, Mann MY, Ramos LR (2007) Financing newborn screening: sources, issues, and future considerations. J Pub Health Management and Practice 13: 207–213.Google Scholar
  83. US General Accounting Office (2003) State NBS Programs. Washington, D.C.: US Government Printing Office, Publication No. GAO-03–449.Google Scholar
  84. Wilson JMG, Jungner F (1968) Principles and practice of screening for disease. WHO Public Health Papers No. 34. Google Scholar
  85. World Health Organization, Scientific Group on Screening for Inborn Errors of Metabolism (1968) Screening for inborn errors of metabolism. WHO Technical Report Series 401: 1–57.Google Scholar
  86. Wolfson M, Wu MM (1988) Postrelational database implementation for newborn screening and tracking. J Med Sys 12: 105–113.CrossRefGoogle Scholar
  87. Yeates G (2007) Health care: funding, facts and future. Policy Opinions March: 69–72.Google Scholar
  88. Zhang YH, McCabe ERB (1992) RNA analysis from newborn screening dried blood specimens. Hum Genet 89: 311–314.PubMedCrossRefGoogle Scholar

Copyright information

© SSIEM and Springer 2007

Authors and Affiliations

  1. 1.Department of PediatricsUniversity of Texas Health Science Center at San AntonioSan AntonioUSA
  2. 2.National Newborn Screening and Genetics Resource CenterAustinUSA
  3. 3.Canadian Organization for Rare DisordersTorontoCanada
  4. 4.OZ Systems InternationalTorontoCanada

Personalised recommendations